Clinical Policy: Perampanel (Fycompa)
Reference Number: CP.PMN.156
Effective Date: 11.16.16
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Perampanel (Fycompa®) is a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist.

FDA Approved Indication(s)
Fycompa is indicated:
- For the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older
- For adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Fycompa is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Partial-Onset Seizures (must meet all):
      1. Diagnosis of partial-onset seizures;
      2. Age ≥ 4 years;
      3. Failure of two preferred alternatives (see Appendix B for examples) unless clinically significant adverse effects are experienced or all are contraindicated;
      4. Dose does not exceed 12 mg per day (1 tablet per day).
   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – Length of Benefit

   B. Primary Generalized Tonic-Clonic Seizures (must meet all):
      1. Diagnosis of primary generalized tonic-clonic seizures;
      2. Age ≥ 12 years;
      3. Failure of two preferred alternatives (see Appendix B for examples) unless clinically significant adverse effects are experienced or all are contraindicated;
      4. Fycompa will be used as adjunctive therapy;
      5. Dose does not exceed 12 mg per day (1 tablet per day).
   Approval duration:
C. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. All Indications in Section I (must meet all):
      1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Fycompa for seizures and has received this medication for at least 30 days;
      2. Member is responding positively to therapy;
      3. If request is for a dose increase, new dose does not exceed 12 mg per day (1 tablet per day).
   Approval duration:
   Medicaid/HIM – 12 months
   Commercial – Length of Benefit

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
         Approval duration: Duration of request or 12 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

   Appendix A: Abbreviation/Acronym Key
   AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
   FDA: Food and Drug Administration

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.
**Drug Class** | **Examples** | **Dose Limit/Maximum Dose**
---|---|---
Anticonvulsants for partial seizures | carbamazepine (Tegretol®), felbamate (Felbatol®), gabapentin (Neurontin®), lamotrigine (Lamictal®), levetiracetam (Keppra®), oxcarbazepine (Trileptal®), phenytoin (Dilantin®), tiagabine (Gabitril®), topiramate (Topamax®), valproic acid (Depakene®), divalproex sodium (Depakote®), zonisamide (Zonegran®) | Varies according to the agent used

Anticonvulsants for tonic-clonic seizures | carbamazepine (Tegretol®), lamotrigine (Lamictal®), levetiracetam (Keppra®), phenytoin (Dilantin®), primidone (Mysoline®), topiramate (Topamax®), valproic acid (Depakene®), divalproex sodium (Depakote®) | Varies according to the agent used

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**Appendix C: Contraindications/Boxed Warnings**
- Contraindication(s): none reported
- Boxed warning(s): serious or life-threatening psychiatric and behavioral adverse reactions

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial-onset seizures</td>
<td>2 mg PO QHS (4 mg if on CYP3A4 enzyme-inducers). May increase based on clinical response and tolerability by increments of 2 mg QD, no more frequently than at weekly intervals. The recommended maintenance dose range is 8 mg to 12 mg QD, although some patients may respond to a dose of 4 mg QD.</td>
<td>12 mg/day</td>
</tr>
</tbody>
</table>

| Primary generalized tonic-clonic seizures | 2 mg PO QHS (4 mg if on CYP3A4 enzyme-inducers). May increase based on clinical response and tolerability by increments of 2 mg QD, no more frequently than at weekly intervals. The recommended maintenance dose is 8 mg QHS. Patients who are tolerating Fycompa at 8 mg QD and require further reduction of seizures may benefit from a dose increase up to 12 mg QD if tolerated. | 12 mg/day |

**VI. Product Availability**
- Tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg
- Oral suspension: 0.5 mg/mL (340 mL)
VII. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Converted to new template, minor changes to verbiage and grammar. References updated.</td>
<td>01.12.17</td>
<td>08.17</td>
</tr>
<tr>
<td>Partial onset-seizures: removed requirement for adjunctive treatment with another AED as Fycompa now approved for monotherapy</td>
<td>08.16.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: policies combined for Commercial and HIM lines of business; new policy for Medicaid; added requirement related to trial and failure of preferred alternatives; Commercial: added age requirement and updated continued therapy to allow continuation of care for seizures; added QL of 1 tablet daily; references reviewed and updated.</td>
<td>04.06.18</td>
<td>08.18</td>
</tr>
<tr>
<td>No significant changes: for partial-onset seizures, modified minimum age requirement from 12 to 4 years of age per updated FDA indication.</td>
<td>10.23.18</td>
<td></td>
</tr>
<tr>
<td>3Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>05.19.19</td>
<td>08.19</td>
</tr>
<tr>
<td>3Q 2020 annual review: no significant changes; references reviewed and updated.</td>
<td>05.04.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical
practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,